Jump to content
  • Announcements

    • Admin

      Do you have a question?   01/27/2017

      Do you have any questions? Do you need information? Please let us know and we will try to help!
    • Admin

      Date Format and Registration   02/02/2017

      Registration & Date Format Please use the following: nn-nn-nnnn where n=number. For example, 6 June 1987: 06-06-1987 You must use "-" format and not "/"
    • Admin

      Blogs!   03/27/2017

      All registered Members can write their own Blog here! Just click on Blog and select a title!
    • Admin

      A new forum: chronic pain   04/27/2017

      We have a new forum called Chronic Pain. Articles, resources and management of pain.
    • Admin

      Registration and Validation   06/03/2017

      Thank you for your Registration! Validation is not automatic and will depend on time zone differences!It ought to be no more than 24 hours. If you do not hear within 24 hours, send me a message using the Contact Us! This is to try and prevent spammers, bots etc! Thank you and hope the LuPUS MB is useful to you!  

Benlysta Formulation for Lupus Gets FDA Nod

Recommended Posts

Benlysta Formulation for Lupus Gets FDA Nod

August 01, 2017 | Lupus

A new subcutaneous formulation of Benlysta (belimumab) has received FDA approval for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy, GSK announced.

This is the first subcutaneous self-injection treatment option for patients with SLE, according to GSK. Patients will be able to administer the medicine as a once-weekly injection of 200 mg, from a single-dose prefilled syringe or a single-dose autoinjector, after receiving training from their health care provider.

This is the second formulation of Benlysta to be granted FDA approval for SLE, GSK noted. The intravenous formulation, approved in 2011, is administered to patients as a weight-based dose of 10 mg/kg, via a 1-hour infusion in a hospital or clinic setting every 4 weeks (after an initial loading phase given on days 0, 14, and 28).

“Lupus can impact the lives of patients in many different ways with varied and often unpredictable symptoms,” said Vlad Hogenhuis, GSK’s Senior Vice President, Head of Specialty Care. “Since it launched in its IV form, thousands of patients worldwide have received treatment with Benlysta. The approval of the new injectable formulation will now provide an additional choice for patients, allowing them to self-administer their medicine at home rather than going to hospitals or clinics for their infusions.”

The approval is based on data from the BLISS-SC phase III pivotal study of more than 800 patients with active SLE. The study measured reduction in disease activity at Week 52 in patients receiving belimumab plus standard of care versus those receiving placebo plus standard of care (assessed by the SLE Responder Index).

The Benlysta subcutaneous formulation will be available in specialty pharmacies in the United States in late August.

Further regulatory submissions for the subcutaneous formulation of Benlysta are under review or planned in other countries during the course of 2017.

Share this post

Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now